Journal of Clinical Endocrinology & Metabolism, Vol 70, 1254-1261, Copyright © 1990 by Endocrine Society

ARTICLES

A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects

J Halse, AG Harris, A Kvistborg, O Kjartansson, E Hanssen, O Smiseth, O Djosland, G Hass and J Jervell
Department of Medicine, National Hospital, Rikshospitalet, University of Oslo, Norway.

Twenty-six acromegalic patients were randomized to treatment with either SMS 201-995 or bromocriptine in increasing doses and were investigated before treatment, after 2, 4, and 8 weeks of treatment, and 2 weeks after discontinuation of treatment. There were two dropouts from the bromocriptine group and one from the SMS 201-995 group. Amelioration of clinical signs and symptoms was seen in both groups during treatment. After 8 weeks mean 12-h GH concentrations had declined from 13.8 +/- 5.2 to 2.9 +/- 4.4 (mean +/- SEM) in SMS 201-995- treated and from 18.8 +/- 7.5 to 5.4 +/- 1.2 micrograms/L in bromocriptine-treated patients. Somatomedin-C concentrations fell from 3.04 +/- 0.36 to 1.43 +/- 0.36 in SMS 201-995-treated and from 2.93 +/- 0.40 to 2.13 +/- 0.27 U/mL in bromocriptine-treated patients. Size reduction of the pituitary tumor was seen in one patient receiving bromocriptine. Gastrointestinal glucose absorption was delayed, and insulin secretion suppressed during treatment with SMS 201-995. Hemoglobin-A1 concentrations remained unchanged in SMS 201-995-treated patients, but declined in the bromocriptine group. Side-effects were common, but usually tolerable, with both treatments. It is concluded that both drugs are of benefit in the treatment of acromegaly.

This article has been cited by other articles:

				S. Melmed, R. Sternberg, D. Cook, A. Klibanski, P. Chanson, V. Bonert, M. L. Vance, D. Rhew, D. Kleinberg, and A. Barkan A Critical Analysis of Pituitary Tumor Shrinkage during Primary Medical Therapy in Acromegaly J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4405 - 4410. [Abstract] [Full Text] [PDF]

				A.-K. Fjeldheim, P. I. Hovring, O.-P. Loseth, P. W. Johansen, J. C Glover, V. Matre, O. K. Olstad, S. Reppe, J. O Gordeladze, S I. Walaas, et al. Thyrotrophin-releasing hormone receptor 1 and prothyrotrophin-releasing hormone mRNA expression in the central nervous system are regulated by suckling in lactating rats Eur. J. Endocrinol., May 1, 2005; 152(5): 791 - 803. [Abstract] [Full Text] [PDF]

				A. Saveanu, E. Lavaque, G. Gunz, A. Barlier, S. Kim, J. E. Taylor, M. D. Culler, A. Enjalbert, and P. Jaquet Demonstration of Enhanced Potency of a Chimeric Somatostatin-Dopamine Molecule, BIM-23A387, in Suppressing Growth Hormone and Prolactin Secretion from Human Pituitary Somatotroph Adenoma Cells J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5545 - 5552. [Abstract] [Full Text] [PDF]

				J. J. Kopchick, C. Parkinson, E. C. Stevens, and P. J. Trainer Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly Endocr. Rev., October 1, 2002; 23(5): 623 - 646. [Abstract] [Full Text] [PDF]

				K. Takeuchi, T. Funakoshi, S. Oomori, and T. Maruo SUCCESSFUL PREGNANCY IN AN ACROMEGALIC WOMAN TREATED WITH OCTREOTIDE Obstet. Gynecol., May 1, 1999; 93(5): 848 - 848. [Full Text] [PDF]

				C. B. Newman, S. Melmed, A. George, D. Torigian, M. Duhaney, P. Snyder, W. Young, A. Klibanski, M. E. Molitch, R. Gagel, et al. Octreotide as Primary Therapy for Acromegaly J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3034 - 3040. [Abstract] [Full Text]

				S. Melmed, I. Jackson, D. Kleinberg, and A. Klibanski Current Treatment Guidelines for Acromegaly J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2646 - 2652. [Abstract] [Full Text]

				U. Renner, T. Arzberger, U. Pagotto, S. Leimgruber, E. Uhl, A. Müller, M. Lange, A. Weindl, and G. K. Stalla Heterogenous Dopamine D2 Receptor Subtype Messenger Ribonucleic Acid Expression in Clinically Nonfunctioning Pituitary Adenomas J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1368 - 1375. [Abstract] [Full Text]

				R. Abs, J. Verhelst, D. Maiter, K. Van Acker, F. Nobels, J.-L. Coolens, C. Mahler, and A. Beckers Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients J. Clin. Endocrinol. Metab., February 1, 1998; 83(2): 374 - 378. [Abstract] [Full Text]